Open Orphan has announced that hVIVO has signed a new contract for an RSV human challenge study clinical trial with a top 3 global pharmaceutical company. The contract shows the Group's ability to convert the existing hVIVO pipeline and engage with the top customers in the industry providing great encouragement for investors in the medium term. Reiterate Buy
10 Aug 2020
Open Orphan* - Major New RSV Challenge Study Contract
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Open Orphan* - Major New RSV Challenge Study Contract
hVIVO plc (HVO:LON) | 28.2 0.2 2.7% | Mkt Cap: 192.2m
- Published:
10 Aug 2020 -
Author:
Andrew Simms -
Pages:
5
Open Orphan has announced that hVIVO has signed a new contract for an RSV human challenge study clinical trial with a top 3 global pharmaceutical company. The contract shows the Group's ability to convert the existing hVIVO pipeline and engage with the top customers in the industry providing great encouragement for investors in the medium term. Reiterate Buy